CorMedix Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of CorMedix Inc Company

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

CorMedix Inc Info



Ticker SymbolCRMD

Company nameCorMedix Inc

IPO dateMar 25, 2010

CEOMr. Joseph Todisco

Number of employees64

Security typeOrdinary Share

Fiscal year-endMar 25

Address300 Connell Drive

CityBERKELEY HEIGHTS

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code07922

Phone19085179500

Websitehttps://cormedix.com/

Ticker SymbolCRMD

IPO dateMar 25, 2010

CEOMr. Joseph Todisco

Company Executives of CorMedix Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Joseph Todisco

Chief Executive Officer, Director

302.20K

--

Mr. Steven W. Lefkowitz

Independent Director

127.65K

-3.77%

Ms. Susan Blum

Chief Financial Officer

69.69K

--

Ms. Janet M. Dillione

Independent Director

53.47K

-31.86%

Ms. Erin Mistry

Executive Vice President, Chief Commercial Officer

29.12K

-54.14%

Mr. Gregory Scott (Greg) Duncan

Independent Director

13.33K

--

Mr. Robert Stewart

Independent Director

11.00K

-69.44%

Mr. Dan Ferry

IR Contact Officer

--

Dr. Alan William Dunton, M.D.

Independent Director

--

Ms. Elizabeth (Liz) Massonhurlburt

Chief Operating Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Joseph Todisco

Chief Executive Officer, Director

302.20K

--

Mr. Steven W. Lefkowitz

Independent Director

127.65K

-3.77%

Ms. Susan Blum

Chief Financial Officer

69.69K

--

Ms. Janet M. Dillione

Independent Director

53.47K

-31.86%

Ms. Erin Mistry

Executive Vice President, Chief Commercial Officer

29.12K

-54.14%

Mr. Gregory Scott (Greg) Duncan

Independent Director

13.33K

--

Revenue Breakdown

FY2025Q2

FY2025Q1

FY2024

No Data

By RegionUSD

Name

Revenue

Proportion

United States

39.74M

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Sun, Sep 14

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

6.42%

Abdalkader (Shaibatalhamd Aymen)

6.22%

The Vanguard Group, Inc.

5.77%

Marshall Wace LLP

3.46%

Citadel Advisors LLC

2.30%

Other

75.83%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

6.42%

Abdalkader (Shaibatalhamd Aymen)

6.22%

The Vanguard Group, Inc.

5.77%

Marshall Wace LLP

3.46%

Citadel Advisors LLC

2.30%

Other

75.83%

Shareholder Types

Shareholders

Proportion

Investment Advisor

22.74%

Investment Advisor/Hedge Fund

13.43%

Hedge Fund

8.73%

Individual Investor

7.55%

Research Firm

1.48%

Pension Fund

0.63%

Bank and Trust

0.28%

Venture Capital

0.06%

Insurance Company

0.03%

Other

45.06%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

298

35.12M

47.05%

+4.14M

2025Q2

280

26.40M

35.51%

-7.69M

2025Q1

281

29.73M

44.27%

-179.25K

2024Q4

252

24.74M

40.82%

-30.08K

2024Q3

228

19.79M

34.25%

-1.78M

2024Q2

217

17.74M

32.28%

-4.09M

2024Q1

218

17.92M

32.60%

-5.73M

2023Q4

217

19.38M

35.35%

-2.82M

2023Q3

208

18.46M

33.68%

-3.54M

2023Q2

197

19.74M

38.10%

+6.18M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

4.80M

6.42%

+485.88K

+11.27%

Jun 30, 2025

Abdalkader (Shaibatalhamd Aymen)

4.65M

6.22%

+4.65M

--

Aug 08, 2025

The Vanguard Group, Inc.

4.31M

5.77%

+675.49K

+18.59%

Jun 30, 2025

Marshall Wace LLP

2.58M

3.46%

+2.35M

+1019.17%

Jun 30, 2025

Citadel Advisors LLC

1.71M

2.3%

+1.61M

+1517.64%

Jun 30, 2025

State Street Investment Management (US)

1.60M

2.15%

+62.52K

+4.06%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.60M

2.14%

+163.40K

+11.40%

Jun 30, 2025

Nuveen LLC

1.45M

1.94%

+1.27M

+740.45%

Jun 30, 2025

Alyeska Investment Group, L.P.

750.00K

1%

+750.00K

--

Jun 30, 2025

Ghisallo Capital Management LLC

750.00K

1%

+750.00K

--

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

Invesco Dorsey Wright Healthcare Momentum ETF

2.14%

SPDR S&P Pharmaceuticals ETF

1.45%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.05%

First Trust Active Factor Small Cap ETF

0.44%

Janus Henderson Small Cap Growth Alpha ETF

0.32%

iShares Micro-Cap ETF

0.2%

Vanguard US Multifactor ETF

0.16%

Vanguard US Momentum Factor ETF

0.13%

Principal U.S. Small-Cap ETF

0.12%

Fidelity Small-Mid Multifactor ETF

0.12%

Invesco Dorsey Wright Healthcare Momentum ETF

Proportion2.14%

SPDR S&P Pharmaceuticals ETF

Proportion1.45%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion1.05%

First Trust Active Factor Small Cap ETF

Proportion0.44%

Janus Henderson Small Cap Growth Alpha ETF

Proportion0.32%

iShares Micro-Cap ETF

Proportion0.2%

Vanguard US Multifactor ETF

Proportion0.16%

Vanguard US Momentum Factor ETF

Proportion0.13%

Principal U.S. Small-Cap ETF

Proportion0.12%

Fidelity Small-Mid Multifactor ETF

Proportion0.12%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data